The Liver Cancer Diagnostics and Therapeutics Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc. According to the report the Liver Cancer Diagnostics and Therapeutics Market is estimated to be $572 USD million and predicted to rise to $ 884.14 USD million with a CAGR of 9.1%. The market is segmented by Type (Primary, Secondary and Benign Liver growths), by Diagnosis (Ultrasound Scans, Confirmatory Needle Biopsy, Endoscopic Ultrasound, Laparoscopy, CT Scan, PET Scan and Magnetic Resonance Imaging (MRI) Scans), by Therapeutics (Hepatocellular Carcinoma, Cholangio carcinoma, Hepatoblastoma and Targeted Therapy), by End-User (Pediatrics and Adults). Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa.
Technological developments for instance non-invasive radiation therapy and rising incidence of cancer are key drivers for the lung cancer diagnostic and therapeutic market. Other factors driving the market are increasing elderly population across the globe, rising number of hospitals and surgical centers and growing demand for minimally invasive cancer treatment techniques. On the other hand, side-effects and risk allied with medications hamper growth of the liver diagnostics and therapeutics market.
Magnetic Resonance Imaging (MRI) scan is the largest segment for diagnosis type due to the advancements in the field of imaging. Hepatocellular Carcinoma is the most widely occurring type of cancer globally; almost 90% liver cancer cases are of HCC.
North America dominates the market, with the U.S. holding a major market share. Factors like easy availability and high acceptance of innovative diagnostic technologies among healthcare specialists and increasing incidence of cancer in the U.S. and Canada are driving the regions market. The Asia-Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the increasing attention of players on this region.
Some of the key contributors in the industry include Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc., Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG, and Bristol-Myers Squibb Company.
Browse through the full report at â€œhttp://www.marketdataforecast.com/market-reports/-global-liver-cancer-therapeutics-market-836/â€ and checkout our recent reports in the Therapeutics category at â€œhttp://www.marketdataforecast.com/research-reports/healthcare/therapeutics-11/â€. For more insights and up-to-date industry news donâ€™t forget subscribing to our newsletters.